1HFY26 Appendix 4D and Half Year Report
| Stock | Careteq Ltd (CTQ.ASX) |
|---|---|
| Release Time | 26 Feb 2026, 3:50 p.m. |
| Price Sensitive | Yes |
Careteq Ltd Reports 1HFY26 Results
- Revenue down 18% to $51,003
- Loss from continuing operations up 22.8% to $922,188
- Subsidiary Embedded Health Solutions to be divested for $5m
Careteq Limited has reported its financial results for the half-year ended 31 December 2025. Revenue from ordinary activities from continuing operations was down 18.0% to $51,003, while loss from ordinary activities after tax from continuing operations attributable to the owners of Careteq Limited was up 22.8% to $922,188. The comprehensive loss for the consolidated entity after income tax amounted to $277,931, up 85.1% from the previous corresponding period. The company has reached the decision to divest its main business, Embedded Health Solutions, subject to shareholder approval. The sale will enable Careteq to recalibrate its balance sheet and better position the company to focus on growing its HMR Referrals marketplace platform for home medication reviews in the home care sector, as well as defend its position against the ongoing ATO matter regarding R&D tax incentive claims.The directors believe the company has reasonable grounds to continue as a going concern, citing the expected cash injection from the Embedded Health Solutions divestment, forecasted working capital requirements, and the ability to raise additional funds if needed. The company has also made further submissions to the ATO in relation to the R&D tax incentive reassessments and continues to believe there is sufficient evidence to substantiate the expenditure.
The proceeds from the sale of Embedded Health Solutions, if approved by shareholders, are intended to be utilized to focus on the growth of Careteq's HMR Referrals platform, recalibrate its balance sheet, and defend its position against the ongoing ATO dispute regarding R&D tax incentive claims.
The company plans to focus on growing its HMR Referrals marketplace platform for home medication reviews in the home care sector following the divestment of Embedded Health Solutions. The company also intends to use the sale proceeds to recalibrate its balance sheet and defend its position against the ATO's R&D tax incentive claims.